Angiotensin I (Human, Mouse, Rat) Mechanisms, Clinical Value

Angiotensin I (Human, Mouse, Rat): Mechanisms, Clinical Value, and Research Applications in Cardiovascular and Renal Physiology

Introduction
Angiotensin I (Ang I) is a decapeptide precursor in the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis in mammals. The peptide sequence of Ang I is highly conserved across species, including humans, mice, and rats, making it a valuable tool for translational research (Kumar et al., 2022, Front. Physiol.). Ang I itself is biologically inactive but serves as the substrate for angiotensin-converting enzyme (ACE), which cleaves Ang I to generate the potent vasoconstrictor angiotensin II (Ang II). This conversion is central to the regulation of vascular tone, aldosterone secretion, and sympathetic nervous system activity (Fyhrquist & Saijonmaa, 2008, J. Intern. Med.). The availability of synthetic Ang I peptides for human, mouse, and rat models, such as those provided by APExBIO Technology LLC, facilitates in vitro and in vivo studies of RAS physiology, pharmacology, and pathophysiology. This paper reviews the mechanism of action of Ang I, its clinical and research value, challenges addressed by its use, supporting literature, experimental data, usage guidelines, and future research directions.

[Related: Z-VAD(OMe)-FMK] Clinical Value and Applications
The renin-angiotensin system is implicated in a wide range of cardiovascular, renal, and metabolic disorders. Ang I, as the immediate precursor of Ang II, is central to understanding and manipulating this system for therapeutic benefit. The clinical value of Ang I lies primarily in its role as a research reagent for:
1. Elucidating the enzymatic activity of ACE and other peptidases involved in RAS.
2. Developing and validating ACE inhibitors and angiotensin receptor blockers (ARBs), which are mainstays in the treatment of hypertension, heart failure, and chronic kidney disease (CKD) (Burnier, 2001, J. Hypertens.).
3. Modeling disease states in animal studies, enabling translational research from rodent models to human physiology.
4. Investigating alternative RAS pathways, such as the generation of angiotensin-(1-7) via neprilysin and its vasodilatory, anti-fibrotic effects (Santos et al., 2018, Hypertension).
5. Studying the impact of genetic or pharmacological manipulation of RAS components in preclinical models.
In clinical research, Ang I infusion tests are sometimes used to assess the functional status of the RAS, particularly in cases of suspected primary aldosteronism or renovascular hypertension (Funder et al., 2016, J. Clin. Endocrinol. Metab.).

Key Challenges and Pain Points Addressed
Several challenges in cardiovascular and renal research are addressed by the availability of high-purity, species-specific Ang I peptides:
- **Species Differences:** The high sequence conservation of Ang I across humans, mice, and rats enables direct comparison of RAS function and pharmacology, reducing translational gaps between preclinical and clinical studies (Kumar et al., 2022).
- **Standardization:** Synthetic Ang I allows for precise dosing and reproducibility in experimental protocols, overcoming variability associated with endogenous peptide extraction.
- **Pathway Elucidation:** By providing a defined substrate, Ang I enables detailed kinetic studies of ACE and other RAS enzymes, supporting the development of more selective inhibitors or modulators (Bernstein et al., 2018, Circ. Res.).
- **Drug Development:** Ang I is essential for screening and characterizing new ACE inhibitors, ARBs, and neprilysin inhibitors, which are critical for managing hypertension and heart failure (Burnier, 2001).
- **Alternative Pathways:** The use of Ang I in research has illuminated non-canonical RAS pathways, such as the ACE2/Ang-(1-7)/Mas axis, which may offer novel therapeutic targets (Santos et al., 2018).
These applications help address persistent challenges in understanding RAS complexity, inter-individual variability in drug response, and the development of resistance to current therapies.

[Related: dactinomycin] Literature Review
A substantial body of literature underpins the use and significance of Ang I in biomedical research:
1. **Fyhrquist & Saijonmaa (2008, J. Intern. Med.):** This review details the RAS cascade, emphasizing the conversion of Ang I to Ang II and the clinical relevance of targeting this pathway in hypertension and cardiovascular disease.
2. **Burnier (2001, J. Hypertens.):** Discusses the pharmacology of ACE inhibitors and ARBs, highlighting the importance of Ang I as a substrate in both drug development and mechanistic studies.
3. **Bernstein et al. (2018, Circ. Res.):** Explores the expanding complexity of the RAS, including alternative enzymatic pathways that process Ang I, and their implications for cardiovascular and renal pathophysiology.
4. **Kumar et al. (2022, Front. Physiol.):** Provides a comparative analysis of RAS components in humans and rodents, validating the use of species-specific Ang I peptides for translational research.
5. **Santos et al. (2018, Hypertension):** Reviews the ACE2/Ang-(1-7)/Mas axis, a protective arm of the RAS, and the role of Ang I as a precursor for alternative bioactive peptides.
6. **Funder et al. (2016, J. Clin. Endocrinol. Metab.):** Offers clinical guidelines for the diagnosis of primary aldosteronism, including the use of Ang I infusion tests to assess RAS activity.
7. **Paul et al. (2006, Am. J. Physiol. Renal Physiol.):** Demonstrates the use of Ang I in animal models to study renal hemodynamics and the effects of RAS blockade.
Collectively, these studies establish Ang I as a foundational tool for both basic and applied research in cardiovascular, renal, and endocrine physiology.

Experimental Data and Results
Experimental studies utilizing Ang I have provided critical insights into RAS function and pharmacological intervention:
- **Enzyme Kinetics:** In vitro assays using synthetic Ang I have characterized the catalytic efficiency of ACE and alternative peptidases. For example, Bernstein et al. (2018) demonstrated that ACE2 can convert Ang I to Ang-(1-9), a precursor to Ang-(1-7), highlighting the complexity of RAS regulation.
- **Pharmacological Studies:** Burnier (2001) reported that administration of Ang I in animal models, followed by ACE inhibition, results in attenuated pressor responses, confirming the central role of ACE in Ang II generation and blood pressure regulation.
- **Translational Research:** Kumar et al. (2022) showed that the hemodynamic effects of Ang I infusion are comparable between human and rodent models, validating the use of species-specific peptides in preclinical studies.
- **Alternative Pathways:** Santos et al. (2018) found that in the presence of ACE inhibitors, Ang I can be diverted to produce Ang-(1-7), which exerts vasodilatory and anti-fibrotic effects, suggesting therapeutic potential beyond classical RAS blockade.
- **Clinical Diagnostics:** Funder et al. (2016) described the use of Ang I infusion tests to differentiate between primary and secondary causes of aldosteronism, aiding in the diagnosis and management of hypertension.
These experimental findings underscore the versatility of Ang I as a research tool and its relevance to both drug development and clinical diagnostics.

[Related: olaparib price] Usage Guidelines and Best Practices
To maximize the utility and reproducibility of Ang I in research, the following guidelines are recommended:
- **Peptide Handling:** Ang I should be reconstituted in sterile, deionized water or physiological saline, aliquoted, and stored at -20°C or below to prevent degradation. Avoid repeated freeze-thaw cycles.
- **Concentration and Dosing:** Optimal concentrations depend on the experimental context. In vitro enzyme assays typically use micromolar concentrations, while in vivo studies in rodents may require intravenous or subcutaneous infusion at doses ranging from 1–100 μg/kg, as established in the literature (Paul et al., 2006).
- **Species Specificity:** Use the appropriate Ang I sequence for the species under investigation to ensure physiological relevance and accurate interpretation of results (Kumar et al., 2022).
- **Controls:** Include negative controls (vehicle only) and positive controls (Ang II or ACE inhibitors) to validate assay specificity and sensitivity.
- **Analytical Methods:** Quantification of Ang I and its metabolites can be performed using high-performance liquid chromatography (HPLC), mass spectrometry, or immunoassays, depending on sensitivity requirements.
- **Ethical Considerations:** All animal studies should comply with institutional and national guidelines for the care and use of laboratory animals.
Adhering to these best practices ensures data quality, reproducibility, and translational value.

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406